SK286497B6 - Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu - Google Patents

Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu Download PDF

Info

Publication number
SK286497B6
SK286497B6 SK986-97A SK98697A SK286497B6 SK 286497 B6 SK286497 B6 SK 286497B6 SK 98697 A SK98697 A SK 98697A SK 286497 B6 SK286497 B6 SK 286497B6
Authority
SK
Slovakia
Prior art keywords
antibodies
activating agent
ifn
cells
lymphotoxin
Prior art date
Application number
SK986-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK98697A3 (en
Inventor
Jeffrey L. Browning
Werner Meier
Christopher D. Benjamin
Original Assignee
Biogen Idec Ma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma, Inc. filed Critical Biogen Idec Ma, Inc.
Publication of SK98697A3 publication Critical patent/SK98697A3/sk
Publication of SK286497B6 publication Critical patent/SK286497B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SK986-97A 1995-01-26 1996-01-26 Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu SK286497B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (2)

Publication Number Publication Date
SK98697A3 SK98697A3 (en) 2000-02-14
SK286497B6 true SK286497B6 (sk) 2008-11-06

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
SK986-97A SK286497B6 (sk) 1995-01-26 1996-01-26 Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu

Country Status (25)

Country Link
EP (2) EP0809510B1 (no)
JP (2) JPH10513161A (no)
KR (2) KR100470739B1 (no)
CN (3) CN1146442C (no)
AT (1) ATE268604T1 (no)
AU (1) AU725351B2 (no)
BG (1) BG62599B1 (no)
BR (1) BR9606808A (no)
CA (1) CA2211443A1 (no)
CZ (1) CZ298711B6 (no)
DE (1) DE69632681T2 (no)
DK (1) DK0809510T3 (no)
EA (1) EA000096B1 (no)
EE (1) EE04453B1 (no)
ES (1) ES2220972T3 (no)
FI (1) FI119359B (no)
HK (1) HK1006356A1 (no)
HU (1) HUP9801746A3 (no)
NO (1) NO322744B1 (no)
NZ (1) NZ303405A (no)
PL (1) PL185364B1 (no)
PT (1) PT809510E (no)
RO (1) RO118634B1 (no)
SK (1) SK286497B6 (no)
WO (1) WO1996022788A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
JP4713738B2 (ja) 1998-10-09 2011-06-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド リンホトキシンβ経路の遮断によるウイルス誘導性全身性ショックおよび呼吸窮迫の逆転
NZ525793A (en) * 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
MXPA05006663A (es) * 2002-12-20 2005-09-30 Biogen Idec Inc Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
EA200900581A1 (ru) 2006-10-20 2009-08-28 Байоджен Айдек Эмэй Инк. Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20110079705A (ko) * 2008-09-30 2011-07-07 제넨테크, 인크. 림포톡신 길항제에 대한 류마티스 관절염 반응을 예측하는 생물학적 마커
US20130224228A1 (en) * 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
AU2016209324B2 (en) 2015-01-20 2020-02-27 Igm Biosciences, Inc. Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
DE69132629T2 (de) * 1990-06-27 2002-04-18 Biogen, Inc. Oberflächenkomplexbildung von lymphotoxin
WO1994013808A2 (en) * 1992-12-04 1994-06-23 Biogen, Inc. LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF

Also Published As

Publication number Publication date
AU4970496A (en) 1996-08-14
CZ236197A3 (cs) 1998-02-18
CN1900116A (zh) 2007-01-24
DK0809510T3 (da) 2004-10-04
SK98697A3 (en) 2000-02-14
WO1996022788A1 (en) 1996-08-01
HK1006356A1 (en) 1999-02-26
PL185364B1 (pl) 2003-04-30
CN1146442C (zh) 2004-04-21
KR19980701816A (ko) 1998-06-25
KR20040102364A (ko) 2004-12-04
JP2007169296A (ja) 2007-07-05
ES2220972T3 (es) 2004-12-16
JPH10513161A (ja) 1998-12-15
BR9606808A (pt) 1997-12-30
CN1177302A (zh) 1998-03-25
HUP9801746A3 (en) 2000-11-28
FI119359B (fi) 2008-10-31
EP0809510A1 (en) 1997-12-03
NO973385L (no) 1997-09-25
NO973385D0 (no) 1997-07-22
EP0809510B1 (en) 2004-06-09
MX9705629A (es) 1997-10-31
CA2211443A1 (en) 1996-08-01
NZ303405A (en) 2000-02-28
EE04453B1 (et) 2005-04-15
FI973118A (fi) 1997-09-25
DE69632681T2 (de) 2005-06-09
KR100475492B1 (ko) 2005-03-14
AU725351B2 (en) 2000-10-12
EA199700144A1 (ru) 1997-12-30
NO322744B1 (no) 2006-12-04
HUP9801746A2 (hu) 1998-11-30
EA000096B1 (ru) 1998-08-27
ATE268604T1 (de) 2004-06-15
KR100470739B1 (ko) 2005-09-02
PL321758A1 (en) 1997-12-22
EP1407781A1 (en) 2004-04-14
EE9700255A (et) 1998-04-15
PT809510E (pt) 2004-09-30
FI973118A0 (fi) 1997-07-25
RO118634B1 (ro) 2003-08-29
BG101855A (en) 1998-04-30
CZ298711B6 (cs) 2008-01-02
BG62599B1 (bg) 2000-03-31
CN1589902A (zh) 2005-03-09
DE69632681D1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
US7459537B2 (en) Anti-lymphotoxin-β receptor antibodies as anti-tumor agents
JP2007169296A (ja) 抗腫瘍因子としてのリンフォトキシン−α／β複合体および抗リンフォトキシン−βレセプター抗体
SK6898A3 (en) Soluble lymphotoxin-'beta' receptors and anti-lymphotoxin receptor and ligand antibodies, as therapeutic agents for the treatment of immunological disease
KR20080023766A (ko) Ｃｄ40 항체 제제 및 방법
NZ275711A (en) Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
US6015559A (en) Fas antagonists
KR100888832B1 (ko) 림프독소 베타 경로의 차단에 의한 바이러스-유도성 전신 쇼크 및 호흡 장애의 반전
MXPA97005629A (en) Linfotoxin-alpha / beta complexes and anti-tetration antibodies of lymphotoxin beta as agents anti-tu
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100126